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Objective: Lipodystrophy syndrome is an unexpected clinical manifestation in patients infected
with HIV and might be a clinical marker of increased risk for cardiovascular diseases (CVDs).
Because hyperhomocysteinemia has been associated with CVD, the goal of the present study was to
investigate homocysteine (Hcy) levels and their association with the factors of lipodystrophy
syndrome in men with HIV.
Methods: Hcy metabolism-related molecules were determined in 13 men infected with HIV with
lipodystrophy (HIVþLIP), 10 men with HIV without lipodystrophy (HIV), and 10 healthy controls (C).
Results: Signiﬁcant (P < 0.05) increased Hcy plasma levels were found in HIV (20.5%) and in
HIVþLIP (35.2%) compared with the control group. Plasma levels of vitamin B12 (HIV, 26.5%;
HIVþLIP, 28.8%) and folate (HIV, 39.1% and HIVþLIP, 49.4%) were signiﬁcantly (P < 0.05) lower in
the two groups of HIV patients compared with control. HIVþLIP men presented raised plasma total
sulfur-containing amino acids (20.1%) and lower total plasma thiol (11.3%) than controls. The same
was not observed in the HIV group. Spearman’s correlation test revealed signiﬁcant (P < 0.05)
association between plasma Hcy and duration of highly active antiretroviral therapy (HAART) and
plasma insulin, as well as plasma adiponectin levels.
Conclusion: Our results demonstrated that HIVþLIP men were more susceptible to disturbances in
Hcy metabolism compared with men infected with HIV without lipodystrophy characteristics.
Duration of HAART treatment, elevated plasma insulin, and low levels of adiponectin seem to be
relevant for the appearance of these Hcy metabolic disorders.
 2013 Elsevier Inc. All rights reserved.Introduction self-report [7]. These alterations resemble those associated withHIV infection is recognized as a chronic, manageable illness
that requires lifelong therapy [1]. A decrease in the incidence of
morbidity and mortality occurred with the emergence of highly
active antiretroviral therapy (HAART), however, signiﬁcant
adverse effects have been linked to HAART, including lipodys-
trophy syndrome (LS) [2–4]. LS is characterized by disturbances
in body fat distribution (lipoatrophy and/or lipohypertrophy)
and in metabolism (dyslipidemia and insulin resistance) [5,6].
Body composition abnormalities are the central deﬁning feature
of LS and are typically identiﬁed by physical examination andor states that there is no
: 055 43 33714139.
).
ll rights reserved.metabolic syndrome and may explain the increased risk for
cardiovascular disease (CVD) [8].
In the past few years, elevated concentration of homocysteine
(Hcy) in the blood has been considered a risk factor for the de-
velopment of CVD [9]. Several studies also have related hyper-
homocysteinemia (HHcy) to several diseases, encompassing
neurodegenerative disease, diabetes mellitus, renal dysfunction,
fatty liver disease, and others [10–13]. Hcy is an amino acid
formed exclusively by demethylation of methionine [14]. In
Hcy synthesis, methionine is activated by adenosine triphos-
phate to form S-adenosylmethionine (SAM). SAM acts primarily
as a universal methyl donor in the synthesis of methylated
compounds [15]. A subproduct of these methylation reactions is
S-adenosylhomocysteine (SAH), which is hydrolyzed to adeno-
sine and Hcy [16]. Hcy can be remethylated to form methionine
by the action of the enzyme methionine synthase, which uses
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The catabolism of methionine is performed by transsulfuration,
with Hcy reacting with serine to form cystathionine in an irre-
versible reaction catalyzed by vitamin B6–dependent enzyme
cystathionine-B-synthase.
Some studies have shown the prevalence of mild to moderate
HHcy in individuals infected with HIV [17,18]. However, the
pathogenesis of HHcy in HIV infection with LS has not clearly
been identiﬁed [17–22]. Vitamin B12 and folate status also are
related to Hcy metabolism and have been poorly explored in
HIV-infected patients especially those with LS [21,23]. Because
the determinants of Hcy level in individuals infected with HIV
who have LS have not been well described, the present study
investigated Hcy levels and their association with the factors of
LS in HIV-infected men.
Methods
Participants
This was a cross-sectional study of asymptomatic HIV-infected patients on
HAART for at least 6mo and HIV-uninfected controls. The studywas conducted in
Medical School Hospital at University of S~ao Paulo (HCFMRP/USP), Brazil. The
protocol was approved by the Ethics Committees of our hospital in accordance
with the ethical standards of the Helsinki Declaration of 1975 (revised in 2000).
All patients were informed about the aims of the study and signed informed
consent before entering the study.
HIV-uninfected controls (C; n ¼ 10) were recruited from hospital employees.
Patients with HIV infection without lipodystrophy (HIV; n ¼ 10) and with lip-
odystrophy (HIVþLIP; n ¼ 13) were recruited from the outpatient clinic of
Infectious Disease HCFMRP/USP. Patients were included if they were male, aged
18 y or more and had a stable weight (10% variation in the past 6 mo). All HIV-
infected patients were excluded if CD4 counts were < 200 copies/mm3 and if
they had presence of acute AIDS-related events.
Criteria for lipodystrophy syndrome
HIV-infected men were included in the HIVþLIP group if a loss in subcuta-
neous fat was detected during physical examination (arms, legs, and face) by the
primary investigator or self-reported by the patient, with or without an increase
in the abdomen, breast size, or the development of buffalo hump [24]. The
diagnosis was conﬁrmed objectively by using an accurate and reproducible
method of dual-energy X-ray absorptiometry (Hologic QDR 4500A scanner,
Hologic Inc, Waltham, MA).
Food intake
Vitamin B intake was determined by the food frequency questionnaire (FFQ)
[25]. The mean habitual frequency of consumption of each food listed in the FFQ
was obtained (how many times) together with the respective time unit (daily,
weekly, or monthly) and the habitual size of the individual portion. The nutri-
tional value of the diets was analyzed with the Dietsys software, version 4.0
(National Cancer Institute, Bethesda, MD, USA). A photograph albumwas used in
order to minimize memory bias and to improve the quality of the information
about the size of the portions [26]. The Estimated Average Requirement (EAR)
values from Dietary Recommendations Intakes were used to estimate the prev-
alence of inadequate intakes from folate and B6 micronutrients [27].
Blood sampling and biochemical analyses
In each case, 10 mL of venous blood (5 mL in heparinized tube and 5 mL in
EDTA vacutainer tube) was collected after a 12-h overnight fast. The blood
sample tubes were centrifuged at 1000 g for 10 min, the plasma was separated,
and the aliquots were stored in eppendorf  tubes at 80C for future analysis.
Total plasma and high-density lipoprotein (HDL)-cholesterol, total choles-
terol, and triglyceride concentrations were measured using an automatic
biochemistry analyser (BT 3000 Plus, Wiener Lab, Bahc¸elievler-_Izmir / Turkey).
Glucose was measured by the glucose hexokinase assay. Plasma-free insulin
and adiponectin were measured using a commercially available kit from
IMMULITE (Immulite 2000, DPCMedlab, USA). Insulin resistancewas estimated
with the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) from
fasting glucose and insulin concentrations using the following formula: insulin
(mIU/mL)  glucose (mmol/L)/22.5.The determination of plasma Hcy levels involved preliminary pretreatment
of the sample with SAH hydrolase and dithiothreitol to release protein-bound
Hcy. Plasma Hcy and relative amino acids in plasma were determined by gas
chromatography (GC-17A Shimadzu, Kyoto, Japan) using the commercially
available kit EZ:Faast Amino Acid Analysis (Phenomenex, Torrance, CA, USA).
Plasma vitamin B12 and folate were determined by chemiluminescence
(IMMULITE Siemens, Los Angeles, USA). Total plasma thiol was assayed
according to the method as previously described [28].
Most of the assaywas determined in duplicates (except for folate and vitamin
B12). The coefﬁcient of variation for all measurements was less than 7%.
Statistical analyses
Statistical analyses were performed using SPSS statistical software version
15.0 (SPSS, Chicago, IL, USA). Values are presented as mean  SD. One-way
analysis of variance followed by Tukey’s post hoc test was applied to reveal
differences among the three studied groups. For categorical variables, the results
are presented as frequencies (%) and c2 test was used to reveal differences. The
Spearman correlation coefﬁcient was calculated to determine possible associa-
tions between continuous variables. In all cases, P < 0.05 was considered
statistically signiﬁcant.Results
All HIV-infected patients had serum antibodies to HIV
determined by enzyme immunoassay and conﬁrmed byWestern
blot. According to the revised criteria of the Centers for Disease
Control and Prevention, they were classiﬁed as infected patients,
although all were asymptomatic and without any opportunistic
infection, at the time of the research. Twenty-three HIV-infected
patients were enrolled in this study (13 with LS according to
criteria previously described). Ten healthy individuals were used
as control group.
Characteristics of the control group and HIV-infected patients
are summarized in Table 1. All participants were men and the
two groups showed similar age. The CD4 counts and duration of
HIV infection, as well as the combination of different anti-
retroviral classes were similar between the HIV and HIVþLIP
groups. Four of the HIVþLIP patients had viral load higher than
500 copies/mm3.
The duration of HAART was higher (P < 0.05) in the HIVþLIP
group comparedwith HIV. LS was conﬁrmed by body composition
alterations with lower fat mass speciﬁcally in the total body and
leg segment of patients from the HIVþLIP group compared with
the control group and the HIV group. The metabolic components
of LS also were evident in HIVþLIP, exhibiting higher levels of
insulin, HOMA-IR index, and triglycerides, as well as lower levels
of HDL and adiponectin comparedwith the other groups (Table 1).
Increased Hcy plasma levels were found in HIV (20.5% and P ¼
0.05) and in HIVþLIP (35.2% and P < 0.01) compared with the
control group (Fig. 1). The prevalence of HHcy (> 10 mmol/L) was
30.4% among all HIV-infected patients. When considered with LS,
HHcy (> 10 mmol/L) was present in 10 % and 46.1% of HIV and
HIVþLIP groups, respectively. No individual was detected with
HHcy in the control group.
Vitamin B12 plasma concentration was signiﬁcantly (P < 0.05)
lower in the HIV (26.5%) and HIVþLIPS (28.8%) groups compared
with control. The samewas observed for folate plasma levels (HIV
39.1% andHIVþLIP 40.9% of reduction) (Table 2). Also, HIV-infected
men with LS presented raised plasma total sulfur-containing
amino acids (20.1%) and lower total plasma thiol (11.3%) than
controls. The same was not observed in the HIV group. Addition-
ally, no differences were found in plasmamethionine and cysteine
levels between groups (Table 2).
Spearman’s correlation test revealed signiﬁcant (P < 0.05)
association between the duration of HAART treatment and Hcy,
vitamin B12, and folate plasma concentrations. Additionally,
Table 1
HIV-related variables, body composition, and metabolic proﬁle for the control
(C), HIV-infected (HIV), and HIV-infected with lipodystrophy (HIVþLIP) groups
C (n ¼ 10) HIV (n ¼ 10) HIVþLIP
(n ¼ 13)
HIV infection
Age (y) 45.1  4.6 41.5  6.2 45.3  5.3
Current CD4 count
(cells/mm3)
_ 477.8  153.8 559.8  74.9
Duration of HIV
infection (mo)
_ 93.7  73.7 114.6  25.8
Duration HAART
treatment (mo)
_ 64.7  4 6.3 111.1  23.4y
NRTI therapy (/%) _ 92.3 100.0
NNRTI therapy (%) _ 61.4 70.1
PI therapy (%) _ 46.7 40.3
Fusion inhibitor (%) _ 8.2 10.0
Body composition
Body weight (kg) 76.8  9.1 73.9  11.3 71.2  10.5
Height (cm) 172.3  4.8 171.0  5.0 171.5  5.8
Body mass index
(kg/m2)
25.8  2.6 25.2  3.2 24.2  3.2
Total body muscle
mass (kg)
57.7  6.1 56.6  7.6 57.4  7.2
Total body fat
mass (kg)
17.5  4.3 16.2  4.7 12.6  4.6*
Leg muscle mass (kg) 10.4  1.4 9.4  1.4 9.5  1.2
Leg fat mass (kg) 2.7  1.2 2.4  0.9 1.2  0.6*
Metabolic proﬁle
Glycemia (mg/dL) 89.2  8.4 97.3  11.5 102.5  20.4
Insulin (mU/mL) 4.4  2.5 10.1  5.7* 14.9  7.8*,y
HOMA-IR index
(mmol/mU)
1.7  0.9 4.3  2.8* 6.8  4.2*
Cholesterol (mg/dL) 190.4  26.25 206.7  37.1 220.4  68.1
Triglycerides (mg/dL) 135.5  27.9 165.2  71.1 364.3  153.1*,y
HDL (mg/dL) 45.3  8.9 43.1  5.4 34.1  11.3*
LDL (mg/dL) 127.8  21.2 130.6  27.1 134.4  56.7
Adiponectin (ug/mL) 6.6  2.0 4.1  2.6* 1.9  1.3*,y
ANOVA, analysis of variance; HAART, highly active antiretroviral therapy; HDL,
high-density lipoprotein; HOMA-IR, Homeostasis Model Assessment of Insulin
Resistance; LDL, low-density lipoprotein; NNRTI, non-nucleoside reverse-tran-
scriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; PI, protease
inhibitor
* Signiﬁcant difference in relation to C (P < 0.05 ANOVA followed by Tukey
post-test).
y Signiﬁcant difference in relation to HIV (P < 0.05 ANOVA followed by Tukey
post-test).
Fig. 1. Plasma homocysteine determined for the control (C, n¼ 10), HIV-infected (HIV,
n ¼ 10) and HIV-infected with lipodystrophy (HIVþLIP, n ¼ 13) groups. P < 0.05 by
ANOVA followed by Tukey post-test.
Table 2
Plasma concentration of sulfur-containing amino acids, vitamin B12, folate, and
thiol total determined for the control (C), HIV-infected (HIV), and HIV-infected
with lipodystrophy (HIVþLIP) groups
C (n ¼ 10) HIV (n ¼ 10) HIVþLIP
(n ¼ 13)
Cysteine (mmol/L) 193.2  24.3 214.8  44.4 231.3  45.8
Methionine (mmol/L) 34.3  5.7 36.5  7.4 43.2  15.1
Total sulfur-containing
amino acids (mmol/L)
229.5  22.3 240.4  42.5 276.8  58.2*
Plasma vitamin B12 (pg/mL) 713.1  110.1 523.5  61.3* 507.7  128.5*
Plasma folate (ng/mL) 11.7  3.4 7.1  1.5* 6.9  2.0*
Plasma thiol total (mmol/L) 429.0  25.1* 425.7  34.4 390.1  49.8*
y Signiﬁcant difference in relation to HIV (P < 0.05 ANOVA followed by Tukey
post-test)
* Signiﬁcant difference in relation to C (P < 0.05 ANOVA followed by Tukey
post-test).
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plasma concentration of insulin, triglycerides, and adiponectin
also were found. The same was found in relation to plasma
vitamin B12 and folate (Table 3).
Folate intake was higher (P< 0.05) in HIVþLIP patients (289.1
 29.5 mg/d) compared with HIV (203.1  23.2 mg/d) and control
(210.9 24.4 mg/d) groups. All groups had folate intake under the
EAR recommendation of 400 mg/d. The result remains the same
when adjusted to the daily energy intake (C, 0.090  0.03 mg/
kcal; HIV, 0.088  0.03 mg/kcal; HIVþLIP, 0.120  0.04 mg/kcal).
There were no differences in daily vitamin B6 intake among the
studied groups (C, 1.7  0.1 mg; HIV, 1.6  0.2 mg; HIVþLIP, 1.9 
0.2 mg). None of the groups had vitamin B6 intake levels below
the EAR recommendations of 1.1 mg/d.
Discussion
The principal aim of this study was to investigate Hcy levels
and their association with the factors of LS in HIV-infected men.
The major ﬁndings of this investigation were as follows:
1. HIV-infected men with LS were more susceptible to distur-
bances in Hcy metabolism, characterized by HHcy, elevatedplasma levels of total sulfur-containing amino acids, and
lower total plasma thiol compared with HIV-infected men
without LS characteristics.
2. Duration of HAART treatment and higher plasma insulin, as
well as low levels of plasma adiponectin appears to be rele-
vant for the appearance of these Hcy metabolic disorders.
3. Low folate and vitamin B12 status, but not intake, were associ-
atedwith themetabolic disorders in HIV-infectedmenwith LS.
LS is characterized by body fat changes (lipoatrophy and/or
lipohypertrophy) and metabolic abnormalities (ie, dyslipidemia;
insulin resistance; and hyperglycemia, hyperlactatemia, or lactic
acidosis) especially found inHIV-infected people on antiretroviral-
based treatment [2,6]. These alterations have been associatedwith
increased risk for CVDs [8]. To date, elevated concentration of Hcy
in the blood has been considered a risk factor for the development
of CVD [9]. Not unexpectedly, recent studies have evaluated Hcy
levels inHIV-positive individuals [22,29–30]. One study [22] found
a high prevalence (28.6%) of HHcy in a population of HIV-positive
patients. Another study [30] also noted elevated plasma Hcy and
lower folate levels inHIV-infected patients receiving stableHAART
for> 6mo comparedwithHIV-infectedHAART-naïve patients and
noninfected individuals. A more recent study [29] found HHcy
associated with thrombophilic abnormalities in HIV-infected
patients compared with the controls with normal Hcy levels. A
Table 3
Univariate correlation (r coefﬁcients of Spearman) among Hcymetabolites and LS
general characteristics
Hcy Vitamin B12 Folate
Duration HAART treatment (mo) 0.40* 0.62y 0.39*
Total body fat mass (kg) 0.26 0.43* 0.33
Leg fat mass (kg) 0.10 0.45* 0.20
Insulin (mU/mL) 0.48y 0.60y 0.40*
Triglycerides (mg/dL) 0.53y 0.31 0.27
HDL (mg/dL) 0.28 0.75y 0.49y
Adiponectin (ug/mL) 0.54y 0.68y 0.65y
HAART, highly active antiretroviral therapy; Hcy, homocysteine; HDL, high-
density lipoprotein; LS, lipodystrophy syndrome
* P < 0.05 by Spearman correlation test.
y P < 0.01 by Spearman correlation test.
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levels of Hcy, after 6 mo of antiretroviral therapy. All together,
these data showHHcy inHIV-infected patients related to the use of
antiretroviral therapy and low folate plasma and red blood cell
levels.
However, few studies have focused on the relation between
LS complication and Hcy metabolism. A 2009 study [19] was the
ﬁrst to demonstrate that Hcy was signiﬁcantly higher in patients
with metabolic syndrome and LS. In accordance with these
results, our data showed that plasma levels of Hcy were higher in
HIV-infected men with LS. HHcy (> 10 mmol/L) was present in
46.1% of men infected with HIV who had LS compared with HIV-
infected men without lipodystrophy (10%), despite no statistical
signiﬁcance between them. Additionally, higher levels of Hcy
were accompanied by signiﬁcantly increased total sulfur-
containing amino acids concentration (20.1%) and decreased
plasma levels of folate (40.9%) and vitamin B12 (28.8%), as well as
total thiol (11.3%) in HIV-infected men with LS compared with
the control group. Also, correlation tests showed associations
between Hcy levels and LS complications. These results de-
monstrate that the HIVþLIP group was more susceptible to
disturbances in Hcy metabolism compared with the men in the
HIV-only group. Also, duration of HAART treatment and insulin
resistance appear to be relevant for the appearance of the Hcy
metabolic disorders.
Nevertheless, the pathophysiological link between HHcy and
LS is poorly known [19,20]. The association between insulin
resistance and some keymolecules in Hcymetabolism have been
tested in recent studies [18,20,31]. Previous studies found that
serum folate and/or vitamin B12 concentrations were indepen-
dently associated with HHcy in HIV-infected patients [20,22,30].
Association between Hcy metabolism key molecules (folate and
vitamin B12) and plasma insulin also was found in the present
study. Our results also showed decreased plasma vitamin B12 and
folate associated with longer exposure to HAART treatment and
increased Hcy levels. However, folate intake was higher in
HIVþLIP patients compared with the other study groups. One
study [18] noted nutritional abnormalities such as decreased
vitamin B12 and folate intake are not responsible for the high
incidence of HHcy observed in HIV-infected patients. These
results suggest that the disturbance in Hcy metabolism and
HHcy related to LS in HIV-infected patients may be not due to
nutritional status. Complications of LS may be linked to
a disturbance in Hcy metabolism. It is possible that HAART may
interfere with Hcy metabolism perhaps at a common point
between remethylation and transsulfuration pathways [18].
Our study demonstrates that adiponectin levels are signiﬁ-
cantly lower in HIV-infected men with LS compared with the
other groups. Adiponectin is exclusively secreted from adiposetissue and has an important role in fatty acid storage and glucose
metabolism [32]. Studies have demonstrated decreased adipo-
nectin levels associated to duration and type of HAART, insulin
resistance, fat distribution, and blood lipids (total cholesterol and
triglycerides) in HIV individuals with lipodystrophy [32–34].
However, the association between adiponectin and Hcy metabo-
lism is poorly known, especially in men infected with HIV. One
study that used both in vivo and in vitro experiments demon-
strated that exogenous Hcy administration reduced gene expres-
sion, protein levels, and secretion of adiponectin in primary
adipocytes [35]. Furthermore, rats fed a high-methionine diet (2%
wt/wt) had HHcy and decreased adiponectin levels in both plasma
and adipose tissue. Our results are in accordance with that of
a 2008 study [35] suggesting an important association between
lower adiponectin levels and Hcy metabolism disorder in
HIV-infected men with LS. However, the exact mechanism of this
interaction needs to be further investigated.
This study has some limitations that need to be considered.
The study design was cross-sectional with a small number of
participants limiting assessment of the possible effect of LS
development, HAART usage, and Hcy levels. Determining
nutrient intake by using food composition tables may limit
coverage of food items and nutrients, especially fortiﬁed food
with folate. Thus, our folate intake values may be understated.
The FFQ used was not speciﬁc for HIV/AIDS patients, which also
is a limitation. Additionally, plasma folate is not the best
parameter to detect folate deﬁciency. A better indicator of the
tissue folate status is its measurement within the erythrocyte,
which reﬂects the turnover of this molecule over the preceding 2
to 3 mo [18]. A recent study [36] showed that formate provides
important information on folate metabolism indicating HHcy
caused by defects in the remethylation and transsulfuration
pathways. Thus, intra-erythrocyte folate and/or formate assay
may be considered in future studies.
In conclusion, our results demonstrated that HIV-infectedmen
with LS were more susceptible to disturbances in Hcymetabolism
compared with HIV-infected without LS characteristics. Duration
of HAART treatment, elevated plasma insulin, and low levels of
plasma adiponectin seem to be relevant for the appearance of
these Hcy metabolic disorders. Our results encourage further
studies to determine speciﬁc pathways and enzyme disturbances
in Hcy metabolism associated to LS in HIV-infected patients.
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